Antidepressant treatment outcome depends on the quality of the living environment: a pre-clinical investigation in mice

PLoS One. 2013 Apr 30;8(4):e62226. doi: 10.1371/journal.pone.0062226. Print 2013.

Abstract

Antidepressants represent the standard treatment for major depression. However, their efficacy is variable and incomplete. A growing number of studies suggest that the environment plays a major role in determining the efficacy of these drugs, specifically of selective serotonin reuptake inhibitors (SSRI). A recent hypothesis posits that the increase in serotonin levels induced by SSRI may not affect mood per se, but enhances neural plasticity and, consequently, renders the individual more susceptible to the influence of the environment. Thus, SSRI administration in a favorable environment would lead to a reduction of symptoms, while in a stressful environment might lead to a worse prognosis. To test this hypothesis, we treated C57BL/6 adult male mice with chronic fluoxetine while exposing them to either (i) an enriched environment, after exposure to a chronic stress period aimed at inducing a depression-like phenotype, or (ii) a stressful environment. Anhedonia, brain BDNF and circulating corticosterone levels, considered endophenotypes of depression, were investigated. Mice treated with fluoxetine in an enriched condition improved their depression-like phenotype compared to controls, displaying higher saccharin preference, higher brain BDNF levels and reduced corticosterone levels. By contrast, when chronic fluoxetine administration occurred in a stressful condition, mice showed a more distinct worsening of the depression-like profile, displaying a faster decrease of saccharin preference, lower brain BDNF levels and increased corticosterone levels. Our findings suggest that the effect of SSRI on depression-like phenotypes in mice is not determined by the drug per se but is induced by the drug and driven by the environment. These findings may be helpful to explain variable effects of SSRI found in clinical practice and to device strategies aimed at enhancing their efficacy by means of controlling environmental conditions.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anhedonia
  • Animals
  • Antidepressive Agents / pharmacology*
  • Behavior, Animal / drug effects
  • Brain / drug effects
  • Brain / metabolism
  • Brain / physiopathology
  • Brain-Derived Neurotrophic Factor / metabolism
  • Corticosterone / blood
  • Depressive Disorder, Major / drug therapy*
  • Depressive Disorder, Major / metabolism
  • Depressive Disorder, Major / physiopathology
  • Depressive Disorder, Major / psychology*
  • Drug Evaluation, Preclinical
  • Environment
  • Fluoxetine / pharmacology*
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Serotonin / metabolism
  • Serotonin Uptake Inhibitors / pharmacology*
  • Stress, Psychological*
  • Treatment Outcome

Substances

  • Antidepressive Agents
  • Brain-Derived Neurotrophic Factor
  • Serotonin Uptake Inhibitors
  • Fluoxetine
  • Serotonin
  • Corticosterone

Grant support

Funding for this study was provided by the Italian Ministry of Health, Ricerca Finalizzata 2009, Fasc. 12AF to FC and Ricerca Finalizzata 2008, Fasc. 10BF to EA, and Fondazione Veronesi 2012 to FC. IB was supported by EU, Marie Curie IEF fellowship for Experienced Researcher n: 302881 - Acronym: MODELMOOD. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.